Contemporary Management of Raynaud’s Phenomenon
DOI:
https://doi.org/10.58931/crt.2024.1354Abstract
Raynaud’s phenomenon (RP) is defined as reversible pallor, and also rubor or cyanosis especially digits and it is very common on the general population. It can be an early sign of a connective tissue disease, especially scleroderma and may negatively impact patients’ quality of life. Lifestyle modifications including smoking cessation, cold-avoidance, and avoidance of medications that could worsen RP should be considered as first-line therapies. For those who are resistant to conservative measures, dihydropyridine calcium channel blockers (CCBs) are the preferred first-line treatment. The majority of treatment trials in RP study nifedipine, but other drugs such as amlodipine and felodipine. Otherwise, there is evidence supporting the use of topical nitrates and oral phosphodiesterase type 5 (PDE5) inhibitors. Intravenous prostaglandins (prostacyclins, PGI2 such as iloprost and PGE1 which is alprostadil) can be used for refractory cases. There remains a paucity of data for the benefit of botulism toxin, fluoxetine, or bosentan for treating RP in these patients.
References
Pauling JD, Hughes M, Pope JE. Raynaud’s phenomenon-an update on diagnosis, classification and management. Clin Rheumatol. 2019 Dec;38(12):3317-3330.
Rubio-Rivas M, Corbella X, Pestaña-Fernández M, Tolosa-Vilella C, Guillen-Del Castillo A, Colunga-Argüelles D, et al. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clin Rheumatol. 2018;37(4):999-1009. doi:10.1007/s10067-017-3936-7
Fernández-Codina A, Cañas-Ruano E, Pope JE. Management of Raynaud’s Phenomenon in Systemic Sclerosis—a Practical Approach. Journal of Scleroderma and Related Disorders. 2019 Jan; doi:10.1177/2397198318823951.
Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL. Prediction and impact of attacks of Raynaud’s phenomenon, as judged by patient perception. Rheumatology (Oxford). 2015;54(8):1443-1447. doi:10.1093/rheumatology/kev002
Block JA, Sequeira W. Raynaud’s phenomenon. Lancet. 2001;357(9273):2042-2048. doi:10.1016/s0140-6736(00)05118-7
Harrison BJ, Silman AJ, Hider SL, Herrick AL. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum. 2002;46(12):3312-3316. doi:10.1002/art.10685
Hudson M, Lo E, Lu Y, Hercz D, Baron M, Steele R. Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum. 2011;63(1):230-238. doi:10.1002/art.30071
Garner R, Kumari R, Lanyon P, Doherty M, Zhang W. Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015;5(3):e006389. doi:10.1136/bmjopen-2014-006389
Watson HR, Robb R, Belcher G, Belch JJ. Seasonal variation of Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 1999;26(8):1734-1737.
Stjernbrandt A, Pettersson H, Liljelind I, Nilsson T, Wahlström J. Raynaud’s phenomenon in Northern Sweden: a population-based nested case-control study. Rheumatol Int. 2019;39(2):265-275. doi:10.1007/s00296-018-4133-y
Nilsson T, Wahlström J, Burström L. Hand-arm vibration and the risk of vascular and neurological diseases-a systematic review and meta-analysis. PLoS One. 2017;12(7):e0180795. doi:10.1371/journal.pone.0180795
Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol. 2016;82(1):6-16. doi:10.1111/bcp.12912
Mohokum M, Hartmann P, Schlattmann P. The association of Raynaud syndrome with β-blockers: a meta-analysis. Angiology. 2012;63(7):535-540. doi:10.1177/0003319711432861
Umair HM, Sandler RD, Alunno A, Matucci-Cerinic M, Hughes M. Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud’s phenomenon: a scoping review. Semin Arthritis Rheum. 2021;51(6):1200-1204. doi:10.1016/j.semarthrit.2021.09.002
Breen ID, Brumfiel CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L, et al. Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open. 2021;4(4):e217934. doi:10.1001/jamanetworkopen.2021.7934
Hansen SW, Olsen N, Rossing N, Rørth M. Vascular toxicity and the mechanism underlying Raynaud’s phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol. 1990;1(4):289-292. doi:10.1093/oxfordjournals.annonc.a057750
Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31a(13-14):2229-2238. doi:10.1016/0959-8049(95)00460-2
Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. 2010;116(10):2322-2331. doi:10.1002/cncr.24981
Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009;48(7):791-795. doi:10.1093/rheumatology/kep039
Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, et al. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol. 2018;45(6):633-691. doi:10.1111/1346-8138.14162
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909
Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44(2):145-150. doi:10.1093/rheumatology/keh390
Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, et al. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2017;12(12):Cd000467. doi:10.1002/14651858.CD000467.pub2
Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick AL. Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2016;2(2):Cd002069. doi:10.1002/14651858.CD002069.pub5
Gliddon AE, Doré CJ, Black CM, McHugh N, Moots R, Denton CP, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007;56(11):3837-3846. doi:10.1002/art.22965
Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999;42(12):2646-2655. doi:10.1002/1529-0131(199912)42:12<2646::Aid-anr21>3.0.Co;2-t
Tucker AT, Pearson RM, Cooke ED, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud’s syndrome: a randomised trial. Lancet. 1999;354(9191):1670-1675. doi:10.1016/s0140-6736(99)04095-7
Curtiss P, Schwager Z, Cobos G, Lo Sicco K, Franks AG, Jr. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol. 2018;78(6):1110-1118.e1113. doi:10.1016/j.jaad.2018.01.043
Qiu O, Chan T, Luen M, Cruz JE, Hermes-DeSantis ER. Use of nitroglycerin ointment to treat primary and secondary Raynaud’s phenomenon: a systematic literature review. Rheumatol Int. 2018;38(12):2209-2216. doi:10.1007/s00296-018-4119-9
Curtiss P, Svigos K, Schwager Z, Lo Sicco K, Franks AG, Jr. Part II: the treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol. 2024;90(2):237-248. doi:10.1016/j.jaad.2022.05.067
Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72(10):1696-1699. doi:10.1136/annrheumdis-2012-202836
Maltez N, Maxwell LJ, Rirash F, Tanjong Ghogomu E, Harding SE, Tingey PC, et al. Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud’s phenomenon. Cochrane Database Syst Rev. 2023;11(11):Cd014089. doi:10.1002/14651858.Cd014089
Raina R, Lakin MM, Agarwal A, Sharma R, Goyal KK, Montague DK, et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology. 2003;62(1):110-115. doi:10.1016/s0090-4295(03)00157-2
Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36(1):25-31. doi:10.1016/s0735-1097(00)00705-1
Pofi R, Gianfrilli D, Badagliacca R, Di Dato C, Venneri MA, Giannetta E. Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work? J Endocrinol Invest. 2016;39(2):131-142. doi:10.1007/s40618-015-0339-y
Pomara G, Morelli G, Pomara S, Taddei S, Ghiadoni L, Dinelli N, et al. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. J Androl. 2004;25(4):625-629. doi:10.1002/j.1939-4640.2004.tb02833.x
Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003;61(4 Suppl 1):8-14. doi:10.1016/s0090-4295(03)00115-8
Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013;14(10):1333-1344. doi:10.1517/14656566.2013.799665
Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 2016;75(6):1009-1015. doi:10.1136/annrheumdis-2014-207001
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;1998(2):Cd000953. doi:10.1002/14651858.Cd000953
Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, et al. Treatment of Raynaud’s phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol. 2001;28(4):786-794.
Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40(9):1038-1043. doi:10.1093/rheumatology/40.9.1038
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;1998(2):Cd000954. doi:10.1002/14651858.Cd000954
Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, et al. Beneficial effect of botulinum toxin A on Raynaud’s phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016;43(1):56-62. doi:10.1111/1346-8138.13030
Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud’s phenomenon: a review. Semin Arthritis Rheum. 2012;41(4):599-603. doi:10.1016/j.semarthrit.2011.07.006
Du W, Zhou M, Zhang C, Sun Q. The efficacy of botulinum toxin A in the treatment of Raynaud’s phenomenon in systemic sclerosis: a randomized self-controlled trial. Dermatol Ther. 2022;35(7):e15529. doi:10.1111/dth.15529
Senet P, Maillard H, Diot E, Lazareth I, Blaise S, Arnault JP, et al. Efficacy and safety of botulinum toxin in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2023;75(3):459-467. doi:10.1002/art.42342
Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud’s phenomenon with the endothelin receptor antagonist bosentan. Rheumatology (Oxford). 2006;45 Suppl 3:iii45-48. doi:10.1093/rheumatology/kel290
Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud’s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford). 2010;49(3):583-587. doi:10.1093/rheumatology/kep413
Korn JH, Mayes M, Cerinic M, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50(12):3985-93.
Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, et al. Bosentan treatment of digital ulcerations related to systemic sclerosis: results of a randomised double-blind placebo-controlled trial. Ann Rheum Dis 2011
Khanna D, Denton CP, Merkel PA, Krieg T, et al. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients with Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA. 2016 May 10;315(18):1975-88. doi: 10.1001/jama.2016.5258. PMID: 27163986
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Rheumatology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
